August 01, 2016 – BRENTWOOD, Tenn.–(BUSINESS WIRE)–PathGroup, one of the largest private providers of anatomic pathology and clinical lab services in the U.S., today announced a recapitalization in partnership with Pritzker Group Private Capital.
Founded by a team of pathologists in 1965, PathGroup is a physician-led company currently working with more than 70 hospitals and thousands of group practices across the U.S. to deliver quality results with unmatched responsiveness. PathGroup’s more than 80 in-house physician experts include a comprehensive spectrum of pathology subspecialty areas supporting the company’s mission to improve patient outcomes through high-quality diagnostics and direct physician contact.
Pritzker Group Private Capital and co-investors including Vesey Street Capital Partners invested alongside PathGroup’s management team and pathologists, who continue to hold a significant ownership stake in PathGroup and will continue to lead the company’s growth as the preferred provider of comprehensive anatomic, clinical and molecular pathology services. “Pritzker Group’s depth of resources, understanding of our business and long-term approach to building market-leading businesses makes them an ideal partner for PathGroup,” said Dr. Ben Davis, chairman, president and CEO of PathGroup. “We’re proud to join with Pritzker Group to support the next chapter in our company’s growth.”
“PathGroup has built an unparalleled reputation over 50 years by providing the highest level of services critical to patient success,” said Michael Dal Bello, healthcare investment partner for Pritzker Group Private Capital. “As a physician-led company, PathGroup truly understands the needs of its customers.” MTS Health Partners served as financial advisor to PathGroup and its shareholders including Primus Capital, which previously led a growth investment in PathGroup in 2009.